Background. Current therapy options for patients with chronic hepatitis C virus (HCV) infection genotype 1 are effective in ,50%. Danoprevir (ITMN-191/RG7227) is a potent, selective, and orally active inhibitor of the HCV NS3/4A serine protease.
Infection with hepatitis C virus (HCV) is a leading cause of chronic liver disease and is associated with a high risk of developing cirrhosis and hepatocellular carcinoma. With the current standard of care (SOC), a combination of pegylated interferon-a (peg-IFN-a) and ribavirin for 48 weeks, a sustained virologic response can be achieved in only 50% of the patients infected with the most prevalent genotype 1 [1] [2] [3] . Furthermore, the SOC is associated with significant adverse effects. Thus, moreeffective and better-tolerated treatment options for HCV infection are needed.
The nonstructural 3/4A (NS3/4A) serine protease processes the HCV polyprotein to generate mature viral proteins. Direct protease inhibition has emerged as a promising target for therapy. The first-generation inhibitors boceprevir and telaprevir are linear peptidomimetic NS3 protease inhibitors that form a covalent adduct with their target [4, 5] . Combination of either rug with the SOC significantly improves the rate of sustained virologic response (SVR) [6, 7] . However, these agents are given 3 times daily in high mass amounts and are associated with significant adverse effects that can lead to patient discontinuation.
A next generation of NS3/4A inhibitors seeks to improve the efficacy, safety, and convenience of this therapeutic intervention. One such inhibitor is danoprevir, a potent, noncovalent, P1 to P3 macrocyclic NS3/4A inhibitor with high exposure in liver tissue but low systemic exposure [8] . In a previous phase 1 trial, twice daily or 3 times daily treatment with danoprevir monotherapy resulted in median decreases in HCV RNA level of up to 3.8 log 10 IU/mL [9] .
The present study assessed the safety and antiviral activity of danoprevir in combination with SOC over 14 days in patients infected with HCV genotype 1 who had not been treated previously.
METHODS

Study Design
This was a phase 1b, randomized, double-blind, placebocontrolled, multiple ascending dose study in treatment-naive patients infected with HCV genotype 1. Patients were randomized to receive either danoprevir or matching placebo, administered in the fed state, for 14 complete days, and a single dose on day 15 . In addition, all patients received the SOC (peg-IFN-a 2a and ribavirin) in accordance with the product labeling. The SOC was provided in the study from day 0 and after the completion of study drug treatment on days 15-44. The 5 lowest dose cohorts consisted of 10 patients randomized (8:2) to receive treatment with danoprevir or placebo equivalent. The highest dose cohort consisted of 9 patients randomized (7:2) to receive treatment with danoprevir or placebo equivalent. Danoprevir was administered orally in soft gelatin capsule form in the following dose regimens: 100 mg 3 times daily, 200 mg 3 times daily, 300 mg 3 times daily, 400 mg twice daily, 600 mg twice daily, and 900 mg twice daily.
Patients were admitted to a phase I research facility on day 0, and the SOC was initiated. Danoprevir treatment was initiated on day 1 and continued until the morning of day 15. Patients were discharged from the research facility on day 16. Safety follow-up visits were performed on day 28 and at the end of the study on day 44. Patients were permitted to continue with the SOC after day 44, beyond the study protocol. Standard clinical and laboratory evaluations were performed at baseline and at regular intervals throughout the study period.
Patients were randomized using an interactive voice response system, which assigned a patient identification number corresponding with treatment assignment (danoprevir or placebo), according to the randomization code. The study was conducted in full accordance with the 1996 Declaration of Helsinki. The study protocol was reviewed and approved by the independent ethics committee at each participating research facility, and written informed consent was obtained from each patient before study screening.
Patients
Eligibility criteria included patients with genotype 1 chronic HCV infection with detectable plasma HCV RNA levels (.1 3 10 4 IU/mL), no previous treatment for HCV infection, an age of 18-65 years, a body mass index (defined as the weight in kilograms divided by the square of the height in meters) of 18-30, and no evidence of cirrhosis during the previous 2 years in a liver biopsy or noninvasive procedure (eg, elastography).
Patients were excluded from the study if they met any of the following criteria: decompensated liver disease; impaired liver function; clinical or histopathologic evidence of cirrhosis; history of non-hepatitis C chronic liver disease; screening positive for hepatitis B surface antigen or HIV infection; history of active malignancy during the preceding 5 years; history of clinically significant cardiovascular or cerebrovascular disease; previous treatment with peg-IFN-a and ribavirin; treatment with growth factors within 3 months before screening; history of drug use within the previous year; regular consumption of .1 glass of alcohol per day for women or .2 glasses of alcohol per day for men; participation in an investigational drug study within 3 months before screening or any prior participation in a study of an experimental HCV therapy; and selected laboratory abnormalities, including serum alanine aminotransferase (ALT) level .5 times the upper limit of the reference range, creatinine clearance ,30 mL/min, or total bilirubin level $26 mmol/L. Pregnant or lactating women, women of childbearing potential, and male partners of pregnant or lactating women were excluded from enrollment. In addition, any patient who, in the opinion of the investigator, was not a suitable candidate for enrollment or was unlikely to comply with the requirements of the study was also excluded from enrollment.
Efficacy evaluable patients were defined as those who received at least 90% of prescribed doses of blinded study drug.
Safety Assessments
Safety assessments included physical examinations, recording of adverse events, vital signs, standard clinical laboratory tests, 12-lead electrocardiogram (ECG), cardiac laboratory tests (troponin and creatinine kinase), and daily patient interviews. Dose reductions of peg-IFN-a and ribavirin because of adverse events were performed according to the product label. Dose reduction or interruption of danoprevir therapy was not allowed.
Viral Kinetics
The antiviral activity of danoprevir was assessed by measuring plasma HCV RNA level at day 1, hours 0, 1, 2, 4, 6, 8, 12, 14, and 16; day 2, hours 0, 2, 4, and 6; and days 3, 6, 9, 12, 15, 16 , and 28 at hour 0. In addition, end of treatment measurements were made at day 15, hour 8 for 3 times daily cohorts and day 15, hour 12 for twice daily cohorts. Plasma HCV RNA levels were quantified using the Roche COBAS TaqMan HCV/HPS Test, version 2.0 (Roche Molecular Diagnostics). The lower limit of quantification was 25 IU/mL and the limit of detection was 9.3 IU/mL. Values less than the lower limit of quantification were imputed as 17.2 IU/mL, and values less than the limit of detection were imputed as 4.65 IU/mL.
Virologic Response Patterns and NS3 Sequence Characterization
Rebound, plateau, and continuous decrease viral response patterns were defined by EOT viral load relative to nadir viral load in a manner similar to that described elsewhere [10] . Virologic rebound was defined as either (1) an EOT viral load increase from nadir of $0.5 log 10 IU/mL or (2) an EOT viral load $2 log 10 IU/mL after a nadir viral load less than or equal to the limit of quantification. Virologic plateau was defined as either (1) an EOT viral load increase from nadir of ,0.5 log 10 IU/mL or (2) an EOT viral load greater than the limit of quantification but ,2 log 10 IU/mL after a nadir viral load less than or equal to the limit of quantification. Virologic profiles not meeting these definitions were classified as continuous decrease. Patients experiencing a rebound or plateau in HCV RNA level or those whose HCV RNA level at EOT was .10 3 log 10 IU/mL
were characterized by population-based sequencing of NS3. For viral resistance testing, viral RNA was extracted from patient samples taken before the first dose on days 1, 3, 7, and 14 at hour 0 with use of the QIAamp Virus BioRobot 9604 kit (Qiagen). NS3 protease sequence was amplified using standard procedures. Sequencing of purified DNA was performed using an Applied Biosystems 3730 DNA analyzer (Applied Biosystems). Each sequence was examined by 2 independent investigators. HCV genotyping was performed with the Trugene HCV 5_NC genotyping kit (Bayer HealthCare) and, when possible, was reclassified by NS3 sequence composition.
Statistical Analysis
No formal prospective calculations of statistical power were made. The sample size was determined on the basis of clinical judgment and historical experience from studies of similar type and duration. Viral kinetic and safety data were summarized using descriptive statistics for each cohort and the pooled placebo group. All patients who received at least 1 dose of study drug were included in the safety analysis. All analyses and tabulations were performed using SAS, version 9.1.3 (SAS Institute).
RESULTS
Baseline Characteristics
A total of 59 patients met all eligibility criteria and consented to participate in the study. One patient withdrew because of Results from liver biopsy and transient elastography (FibroscanÒ) were available in 11 and 48 patients, respectively, staging according to references [11] and [12] . a family emergency after 1 dose of study drug, and 1 patient withdrew because of poor venous access after 4 doses of study drug. A third patient (administered 100 mg 3 times daily) missed 6 danoprevir doses during days 12-14 but was included in efficacy analyses, because .90% of danoprevir doses were administered. All other patients received 100% of planned danoprevir doses. Demographic and baseline characteristics, including median HCV RNA levels, were similar across treatment groups and dosing cohorts (Table 1) .
Safety
Danoprevir was safe and generally well tolerated. There were no clinically significant laboratory or ECG abnormalities, and no patient discontinued treatment because of an adverse event.
Adverse events were generally mild and transient and without association to treatment groups or dose levels. There were no study drug-related serious adverse events reported; one patient experienced a single unrelated serious adverse event of viral gastroenteritis. One patient showed an elevated indirect bilirubin level (1.6 mg/dL) at day 7 without an increase in ALT level. The elevation was considered as not clinically significant by the investigator, and treatment was continued with no further increase of indirect bilirubin levels. At the end of the study treatment, indirect bilirubin levels were just slightly elevated (1.4 mg/dL), and on day 28, the values had normalized (1.2 mg/dL). None of these events resulted in premature discontinuation of study drug, and all events resolved spontaneously without sequelae. Adverse events are summarized in Table 2 .
Viral Kinetics
Treatment with danoprevir in combination with the SOC resulted in rapid and robust reductions in plasma HCV RNA level, compared with treatment with placebo in combination with the SOC ( Figure 1A) . Median viral kinetic profiles were similar across danoprevir treated groups and distinct from placebo-treated groups. Median viral kinetics for genotype 1a and 1b were indistinguishable across all cohorts regardless of danoprevir schedule ( Figure 1B ) and were very similar for each danoprevir dose group (data not shown). Virologic responses are summarized in Table 3 . After 14 days of triple combination therapy, the median change in HCV RNA level from baseline exceeded 25 log 10 IU/mL in 5 of 6 danoprevir dose groups, with the exception being the 400 mg twice daily dose group (median change, 24.7 log 10 IU/ mL). In the best performing twice daily and 3 times daily dose groups, the median EOT change in HCV RNA level was 25.4 log 10 IU/mL and 25.7 log 10 IU/mL, respectively. Placebo administered on a twice daily or 3 times daily schedule in combination with the SOC resulted in median changes in HCV RNA level of 22.6 log 10 IU/mL or 22.0 log 10 IU/mL, respectively. 
NOTE.
1 In 3 or more patients.
At EOT, the percentage of patients with HCV RNA levels below the limit of quantification (,25 IU/mL) ranged from 57% (4 of 7 patients) to 88% (7 of 8), depending on danoprevir dose group. The percentage of patients with HCV RNA levels below the limit of detection (,9.3 IU/mL) ranged from 13% (1 of 8 patients) to 57% (4 of 7), depending on danoprevir dose group. In the pooled placebo groups, the percentage of patients with an HCV RNA level below the limit of quantification was 8% (1 of 12 patients), and no patients had an HCV RNA level below the limit of detection.
Median reductions persisted after cessation of danoprevir treatment. At day 28, the median change in HCV RNA level ranged from 24.4 log 10 IU/mL (600 mg twice daily group) to 25.8 log 10 IU/mL (200 mg 3 times daily group), compared with 23.3 log 10 IU/mL for the pooled placebo groups (data not shown).
Virologic Response Patterns and NS3 Sequence Characterization
Forty-one of the 45 danoprevir-treated patients experienced a continuous decrease in HCV RNA level during danoprevir administration. The remaining 4 danoprevir-treated patients had a continuous decrease profile to the penultimate time point (day 15, hour 0) and an increase in HCV RNA level of #0.43 log 10 IU/mL to EOT (day 15, hour 8 or hour 12 for 3 times daily and twice daily dose groups, respectively). These patients were classified as experiencing virologic plateau by a stringent definition. Two such patients, one each infected with genotype 1b and 1c, were administered the lowest 3 times daily dose of danoprevir (100 mg 3 times daily) (Figure 2A) . The patients infected with genotype 1c missed 6 doses of study treatment on days 12-14 but received .90% of treatment and was included in the efficacy evaluable population as per protocol. The 2 additional patients classified as experiencing virologic plateau, both infected with genotype 1a, were administered 600 mg twice daily ( Figure 2B ). Of note, 4 of the 12 placebotreated patients showed a similar increase in HCV RNA level between the penultimate measurement and EOT (data not shown).
All 4 of the patients receiving danoprevir and classified as experiencing virologic plateau displayed an 2 log 10 IU/mL lesser reduction in HCV RNA level at EOT, compared with the median profile of continual decrease in patients in their respective dose groups (Table 4 ). However, the 2 patients who plateaued in the 100 mg 3 times daily group appeared to have a lesser first phase decrease in HCV RNA level, compared with the median value in other patients in this dose group (Figure 2A) . In contrast, the 2 patients with plateau who were administered 600 mg twice daily had a comparable first phase but reduced second phase decrease in HCV RNA level, compared with the median profile in all other patients receiving 600 mg twice daily ( Figure 2B) .
Population-based sequencing of NS3 revealed that a treatmentemergent lysine for arginine substitution at position 155 (R155K) at days 6 and 9 in a patient in the 600 mg twice daily group who experienced plateau (patient 03-8503) ( Figure 2B and Table 4 ). HCV RNA could not be amplified for this patient at EOT (day 15). The second patient who experienced plateau who received 600 mg twice daily did not carry prevalent sequence changes in NS3 either during danoprevir treatment or at EOT, as determined by population-based analysis. Standard approaches failed to amplify NS3 from the 2 patients who experienced plateau and received 100 mg 3 times daily at any available time point, except for at day 6 for patient 05-8106; there were not any substitutions in NS3 relative to sequence identity in this patient at baseline. Of interest, population-based sequencing of NS3 at baseline identified a single patient with continuous decrease of genotype 1b that carried a mixture of aspartic and glutamic acids at position 168 (D168E). This patient was administered 400 mg twice daily and had an HCV RNA level reduction at EOT that was superior to the median profile of all other patients in this cohort (Table 4) . Moreover, both first and second phase components of HCV RNA decrease in this patient were similar if not superior when compared with the median profile in all other patients in this dose group (Figure 3) .
ALT Levels
Median baseline serum ALT levels were above the normal range for all cohorts and ranged from 40.5 U/L (pooled placebo group) to 70.5 U/L (100 mg 3 times daily). Throughout the study and at EOT, median serum ALT levels showed a higher decrease in all danoprevir-treated dose groups, compared with the pooled placebo group, with 200 mg 3 times daily having the largest median change of 236.0 U/L from baseline to EOT. The pooled placebo treatment groups experienced a median change of 22.5 U/L from baseline to EOT. Among patients with elevated serum ALT levels at baseline, levels normalized by EOT in 16 (42%) of 38 danoprevir-treated patients and 0 (0%) of 6 placebo-treated patients.
DISCUSSION
Danoprevir is a potent inhibitor of HCV NS3/4A protease activity that provides multi-log 10 reductions in HCV RNA level in short-duration monotherapy [9] . The compound has been studied for short durations in patients with chronic HCV infection in combination with the nucleoside inhibitor RG7128 [13] and is currently in phase 2b clinical development in combination with the standard of care.
In the current study, danoprevir was safe and well tolerated, with an adverse effect profile comparable to that of SOC. There were no drug related severe adverse events or discontinuations of study drug. One patient receiving 200 mg twice daily experienced an elevation of indirect bilirubin level at day 7 that returned to normal by day 28 without interruption of therapy. Rash, an adverse effect associated with many other NS3/4A protease inhibitors [6, 7] , was not reported. This may reflect the different UV absorption characteristics of danoprevir and other NS3/4A protease inhibitors, because the latter carry conjugated aromatic P2 systems that absorb in a region of the UV spectrum associated with phototoxicity [14, 15] . The unique isoindolene P2 group of danoprevir does not absorb in this region of the UV spectrum, which rationalizes the absence of this toxicity.
Over the 14-day treatment period with danoprevir, no safety signal was seen in the 900 mg twice daily dosing groups. However, dosing of 900 mg danoprevir twice daily over 12 weeks treatment duration in combination with peg-IFN-a 2a and ribavirin showed ALT level elevations (.10 times the upper limit of normal) in 6 % of the patients [16] . As a result, the 900 mg arm was stopped in subsequent studies. Subsequent studies have shown that, with a ritonavir-boosting strategy, lower doses of danoprevir are needed without a lack of efficiency but with a better safety profile [17] .
Antiviral effects of danoprevir in combination with SOC were comparable in twice daily and 3 times daily dosing regimens over 14 days of treatment. Reductions .5 log 10 IU/mL were observed in the twice daily and 3 times daily cohorts, with the exception of the lowest twice daily dose that showed 3 Defined as ,9.3 IU/mL. 4 Defined as EOT HCV RNA .0.5 log 10 IU/mL above nadir, or an EOT viral load $2 log 10 IU/mL if an on treatment value was ,25 IU/mL (LLOQ). 5 One patient received less than 90% of prescribed dose and was excluded from efficacy analyses. a 4.7 log 10 IU/mL reduction. Differences were observed in the rates of HCV RNA negativity after 14 days of treatment. However, it is unclear whether these differences reflect different antiviral effect or simply result from the small number of patients in each dose group. Only 4 of the 45 danoprevir-treated patients experienced a virologic plateau during the 14-day treatment period, and no patient showed a virologic rebound during treatment with danoprevir. Because of the small number of patients with a lesser viral response in this study, a valid relationship between pharmacokinetic parameters and viral kinetic parameters cannot be established. This issue needs to be addressed in additional trials with larger number of patients and longer treatment periods.
An early reduction of HCV RNA level that has been observed with other direct acting antiviral agents in combination with the SOC is associated with significant rates of rapid virologic response, early virologic response, and sustained virologic response [6, 7] . Thus, this study suggests that twice daily dosing may be an effective schedule for danoprevir administration.
Similar to other NS3/4A protease inhibitors, danoprevir monotherapy is associated with the emergence of resistance in approximately one-third of patients [10, 18] . Combination with the SOC greatly reduces the incidence of viral escape for other NS3/4A protease inhibitors [6, 7] . In the present study, no patient treated with danoprevir and SOC demonstrated a rebound in HCV RNA level .0.5 log 10 IU/mL. R155K was observed in all patients who experienced viral escape during danoprevir monotherapy [18] . In the present study, R155K was observed by population-based sequencing in a single patient within the first week of study. Despite the early appearance of R155K in this patients with plateau, viral loads did not rebound, as is clearly observed in danoprevir monotherapy [18] , indicating that the SOC is able to suppress R155K-associated viral rebound under certain circumstances. D168E was previously identified during in vitro selection for danoprevir-resistant NS3 variants [19] and associated with HCV RNA rebound during danoprevir monotherapy in a minority of patients infected with genotype 1b [18] . Of interest, in the current study, a danoprevir-treated patient in the lowest twice daily dose group (400 mg twice daily) carried D/E168 at baseline but experienced a continuous decrease in HCV RNA level, with kinetics indistinguishable from all other patients who experienced a continual decrease in HCV RNA level. Similarly, the combination of danoprevir and the nucleoside inhibitor RG7128 was able to suppress a D168E viral variant [13] . Thus, danoprevir in combination with SOC appeared to be sufficient to suppress HCV carrying D/E168 over 14 days in this pilot study, although larger studies will be required to confirm this preliminary finding. In summary, the present study demonstrated danoprevir to be safe and well tolerated when used for 14 days in combination with the SOC. Antiviral responses were similarly robust in twice daily regimens and 3 times daily regimens. No patient experienced a rebound in HCV RNA while receiving danoprevir, and at the dose levels used in this study, danoprevir in combination with the SOC was able to prevent rebound of HCV in variants that display reduced sensitivity to danoprevir. Further clinical investigation to define the safety profile and efficacy of this compound is warranted.
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